Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.
The STRENGTH trial has drawn a slew of reactions from cardiologists and while they examined different agents, some have used the data to draw comparisons and question the results of the REDUCE-IT trial. After a slide from the presentation of the STRENGTH trial questioned the results of REDUCE-IT based on the results of their own trial examining AstraZeneca’s omega-3 CA (Epanova), it sparked an ongoing debate among cardiologists.
Since the presentation, the subject of mineral vs corn oil placebos, DHA vs EPA, and the overall designs of both the STRENGTH and REDUCE-IT trials have become topics of discussion. Among those taking to social media to share their thoughts on the debate was principal investigator from the REDUCE-IT trial, Deepak Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital. To learn more about the differences between the combined EPA-DHA agent examined in STRENGTH and icosapent ethyl, we reached out to Bhatt and that conversation is the subject of the most recent AHA 2020 House Call.